ArticleJACC. CardioOncology2019
Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines.
Article in JACC. CardioOncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2025Pooled it
- Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.European heart journal. Cardiovascular pharmacotherapy · 2023Trial
- Strain imaging in heart failure: from early detection to prognostic assessment.ESC heart failure · 2026Review
- Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study.JACC. CardioOncology · 2026Article
- The emerging role of echocardiography-based techniques in cardio-onco-hematology.Frontiers in oncology · 2026Review
- PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors.Journal of the American Heart Association · 2025Observational
- Nanoencapsulation of ferrocene incorporated thiourea and doxorubicin for treatment of acute myeloid leukemia.BMC cancer · 2025Article
- CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.Cardio-oncology (London, England) · 2025Article
- Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.JCO oncology practice · 2025Article
- Predictive Value of Baseline Left Ventricular Global Longitudinal Strain for Cardiac Dysfunction in Patients with Moderate to High Risk of Cancer Therapy-Related Cardiovascular Toxicity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.Current cardiology reports · 2025Review
- Integrative speckle-tracking echocardiography for the early detection and prediction of cancer therapy-related cardiac dysfunction.Cardio-oncology (London, England) · 2025Article
- Article
- Acute and Chronic Cardiovascular Adverse Events in Patients with Acute Myeloid Leukemia: A Systematic Review.Cancers · 2025Review
- Chemotherapy-Associated Cardiotoxicity: A Silent Threat Evidenced in a Retrospective Cohort Study.Cureus · 2025Article
- Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches.European cardiology · 2025Review
- Novel insights and clinical perception of the patients with acute leukemia transferred to ICU: a multi-center retrospective study spanning 10 years.Frontiers in medicine · 2025Article
- Acute heart failure in patients with hematologic malignancies: A nationwide analysis 2016-2021.SAGE open medicine · 2025Article
- Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2024Review
- Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia.The American journal of cardiology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesThe purpose of this study was to investigate the occurrence and develop a risk score for heart failure (HF) in acute leukemia.
backgroundKnowledge is scarce regarding the incidence and risk factors of symptomatic HF in patients with acute leukemia.
methodsBaseline clinical and echocardiographic parameters, including indices of cardiac function (left ventricular ejection fraction and myocardial strain [global longitudinal strain; GLS]), were obtained in 450 patients with acute leukemia treated with anthracyclines, before chemotherapy initiation. Potential risk factors for HF were evaluated using Fine and Gray's regression analysis, and from this, a 21-point risk score was generated.
resultsForty patients (8.9%) developed HF. The HF risk score included a baseline GLS >-15% (indicative of greater impairment) (6 points), baseline left ventricular ejection fraction <50%, pre-existing cardiovascular disease, acute myeloid leukemia (4 points each), cumulative anthracycline dose ≥250 mg/m
conclusionsWe developed a baseline risk score to determine risk of HF in patients with acute leukemia. Additional studies are needed to determine the external validity of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.